NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
Estimated value
—
Awarded value
—
Suppliers
26
Lots
2
Published
21 Jul 2026
Description
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Scope
- Reference
- C414060
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2026 to 31 Aug 2028Possible extension to 31 Aug 2030
With an option or option(s) to extend for a further 24 months.
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomLondon, United KingdomSouth East England, United KingdomSouth West England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated only in the procurement documents | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 2 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHR/25/5730/01 - Tranche B for NOFE and MAE | £846.1m | complete |
| 2 | CM/PHR/25/5730/02 - Natalizumab for London & SOFE | £31.5m | complete |
Award 1· 24 suppliers
Awarded —
Award 2· 2 suppliers
Awarded —
Total lots
2
Awarded
2
Estimated total
£877.7m
Awarded total
—
CM/PHR/25/5730/01 - Tranche B for NOFE and MAE
Start
31 Aug 2026
End
31 Aug 2028
Estimated
£846.1m
CPV
CM/PHR/25/5730/02 - Natalizumab for London & SOFE
Start
31 Aug 2026
End
31 Aug 2027
Estimated
£31.5m
CPV
Other contracts from NHS England
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to ACCORD-UK LTD· 4
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 10 Jul 2026 |
| Generic Drugs – Injections/Infusions 2 | contract | — | 02 Jul 2026 |
| SARS-CoV-2 Adult Vaccine Supply (2026) | contract | £1 | 25 Jun 2026 |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 | contract | — | 23 Jun 2026 |